Search Results
Apr 01, 2026, 09:00 ET NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky
YORK, April 1, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities of a pending securities class action.
More news about: Levi & Korsinsky, LLP
Mar 31, 2026, 12:00 ET Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
NKTR).
More news about: Glancy Prongay Wolke & Rotter LLP
Mar 31, 2026, 09:00 ET NKTR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Nektar Therapeutics Securities Lawsuit -- The Gross Law Firm
March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR).
More news about: The Gross Law Firm
Mar 31, 2026, 02:03 ET NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.So
More news about: THE ROSEN LAW FIRM, P. A.
Mar 29, 2026, 08:35 ET NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NASDAQ: NKTR) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP
Mar 28, 2026, 12:36 ET Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting
therapeutic potential of rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are investigational agents and continued
More news about: Nektar Therapeutics
Mar 27, 2026, 15:36 ET Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
NKTR). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NEKTAR THERAPEUTICS (NKTR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE MAY 5, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE
More news about: Law Offices of Howard G. Smith
Mar 26, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv-
More news about: Pomerantz LLP
Mar 26, 2026, 09:00 ET NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Hiding Enrollment Protocol Failures: SueWallSt
March 26, 2026 /PRNewswire/ -- SueWallSt encourages investors who suffered losses in Nektar Therapeutics (NASDAQ: NKTR) to contact the firm. Those who purchased NKTR securities between February 26, 2025 and December 15, 2025 may be entitled to recover damages.
More news about: SueWallSt.com
Mar 25, 2026, 22:59 ET NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.So
More news about: THE ROSEN LAW FIRM, P. A.
Mar 25, 2026, 17:10 ET Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
NKTR) have opportunity to lead the securities fraud class action lawsuit.
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Mar 25, 2026, 09:00 ET NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky
YORK, March 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities of a pending securities class action.
More news about: Levi & Korsinsky, LLP
Mar 24, 2026, 09:00 ET NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit -- The Gross Law Firm
March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR).
More news about: The Gross Law Firm
Mar 23, 2026, 22:09 ET Robbins LLP Urges NKTR Stockholders Who Lost Money Investing in Nektar Therapeutics to Contact the Firm for Information About Leading the Class Action
Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that
More news about: Robbins LLP
Mar 23, 2026, 02:10 ET Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of NKTR during the class period listed are encouraged
More news about: DJS Law Group LLP
Mar 23, 2026, 01:10 ET NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Mar 21, 2026, 01:52 ET NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.So
More news about: THE ROSEN LAW FIRM, P. A.
Mar 20, 2026, 10:00 ET Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting
therapeutic potential of rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin, NKTR-0165, NKTR-0166 and NKTR-422 are investigational agents and continued
More news about: Nektar Therapeutics
Mar 20, 2026, 04:06 ET Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of NKTR during the class period listed are encouraged
More news about: DJS Law Group LLP
Mar 20, 2026, 04:02 ET NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
NKTR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Mar 19, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 26-cv-
More news about: Pomerantz LLP
Mar 19, 2026, 09:00 ET NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: SueWallSt
YORK, March 19, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities of a pending securities class action.
More news about: SueWallSt.com
Mar 18, 2026, 09:15 ET NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky
YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities of a pending securities class action.
More news about: Levi & Korsinsky, LLP
Mar 17, 2026, 09:00 ET NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit -- The Gross Law Firm
March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR).
More news about: The Gross Law Firm
Mar 16, 2026, 16:57 ET NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
LLP, a leading national securities law firm, is investigating potential claims against Nektar Therapeutics, Inc. ("Nektar" or the "Company") (NASDAQ: NKTR) and reminds investors of the May 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed
More news about: Faruqi & Faruqi, LLP